Glyscend Therapeutics

About

Glyscend Therapeutics is a clinical-stage biotechnology company based in Boston, MA, focused on developing innovative oral therapies for Type 2 Diabetes and obesity. The company employs fewer than 25 people and has a leadership team with extensive experience in life sciences, including CEO Sapan Shah, Ph.D. Glyscend's primary offering is a novel class of gut-targeted polymer therapeutics that mimic the effects of bariatric surgery without invasive procedures. Their lead product candidate, GLY-200, is an orally administered medicine that targets gut-mediated metabolic signaling. Clinical trials have shown that GLY-200 significantly reduces postprandial glucose levels and body weight. As of June 2024, the drug is in Phase 2 clinical development, with the first patient dosed in an obesity trial. Glyscend aims to provide non-invasive treatment options for individuals with Type 2 Diabetes, those who are overweight, and patients with obesity.